Model-based prediction on clinical doses for cannabinoids therapy is beneficial in the clinical setting, especially for seriously ill patients with both altered pharmacokinetics and pharmacodynamic responses. The objective of this article is to review the currently available PK and/or PD models of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to highlight the major issues for modelling this complex therapeutic area. A systematic search was conducted in the electronic databases PubMed and EMBASE using the key words 'cannabis', 'cannabinoid', 'tetrahydrocannabinol', 'THC', 'cannabidiol', 'CBD', 'pharmacokinetic model', 'pharmacodynamics model' and their combinations. Twelve empirical PK and/or PD models for THC for humans were identified. Among them, ten were developed from data of healthy participants and two were from ill patients. Models for CBD were not found. Model-based prediction on appropriate doses for cannabinoids therapy for ill patients is currently limited due to insufficiency of relevant PK and PD data. High-quality PK and PD data of cannabinoids for patients with different illnesses is needed for model development. Mechanism-based PK and PD models are promising for improved predictive dosing performance for ill and comorbid patients.
Introduction
Requests to access medicinal cannabis by the community has significantly increased due to a perceived therapeutic benefit [1] . As the most well-characterized cannabinoid in cannabis, Δ 9 -tetrahydrocannabinol (THC) has several therapeutic applications, e.g. for cachexia in acquired immune deficiency syndrome (AIDS) or cancer, nausea and vomiting in cancer patients receiving chemotherapy, chronic neuropathic pain management, spasticity in multiple sclerosis, and others [2, 3] . THC is a direct partial agonist which binds to G protein-coupled cannabinoid CB1 and CB2 receptors located throughout the body, including in the brain (CB1) and the immune system (CB2) [4, 5] . Another clinically important phytocannabinoid is cannabidiol (CBD), which has been attracting increasing attention in therapeutic applications for its antiepileptic, anxiolytic, antipsychotic, antiemetic, and anti-inflammatory properties [6] [7] [8] . CBD does not appear to act directly at CB1 receptors and also shows low affinity at CB2 receptors [9] . Some have suggested that CBD acts as a non-competitive inverse agonist, thereby blocking the ability of agonists such as THC to subsequently activate CB1 and/or CB2 receptors [10] . In addition to further elucidating the science and clinical pharmacology of these components, little is known about appropriate doses to give benefit and minimize toxicity. In general, model-based approaches are important tools for integrating data, knowledge and mechanisms to aid in arriving at rational decisions regarding drug use and development [11] . As with many other drugs, the modelling technique is a very useful tool for understanding better the pharmacokinetics (PK), pharmacodynamics (PD) of cannabinoids. Appropriately developed and validated PK model can often predict well the time-concentration profiles of cannabinoids as well as the corresponding C max , t max , AUC, bioavailability and half-life, etc. Combination of appropriate PK and PD models can describe the dose-concentration-effect relationship of cannabinoids. These models, for instance, can be used for dosing optimization to achieve a favourable clinical outcome by considering the clinically relevant features of specific patient(s) and for clinical trial design [12] . The aim of this article is to review the currently available PK and/or PD models of THC and CBD, to examine available data to develop the models and to highlight the major issues for modelling this complex therapeutic area.
Methods
A systematic literature search was conducted in the electronic databases PubMed and EMBASE. The key words used include 'cannabis', 'cannabinoid', 'tetrahydrocannabinol', 'THC', 'cannabidiol', 'CBD', 'pharmacokinetic model', 'pharmacodynamics model' and their combinations. This search focused on the relevant models and data on humans published up to 1 March 2018.
Results and discussion
A total of 13 studies were identified on PK and/or PD models for THC for humans. Eleven studies were conducted with healthy cannabis users/non-users and two were conducted with ill patients (amyotrophic lateral sclerosis and multiple sclerosis). The drug was administered via the smoking route in four studies [13] [14] [15] [16] [17] [18] [19] , orally in four [18] [19] [20] [21] , by IV in four [18, 20, 22, 23] and by vaporized THC inhalation in two [12, 18] . All the models reported were empirical PK and/or PD models. A brief summary containing some key features of the models is presented in Table 1 .
Most of these models predict some basic PK variables such as C max , t max , AUC, and characterize different administration routes relatively well. However, the THC data used for developing these models was based on plasma concentrations measured within~10 h post-dose time. This is significantly shorter than the commonly reported terminal half-life of 20-30 h [22, 24, 25] . Most THC clinical studies chose to collect plasma samples up to~10 h because (1) the pharmacodynamic effects (e.g., subjective high, heart rate acceleration) have returned to baseline after 10 h [25, 26] , and (2) plasma concentration usually is very low after 10 h and it is difficult to analyse (i.e., below the lower limit of quantification of most assays). THC PK models developed from the data of this kind of studies can be used only for describing short-term pharmacokinetics. They are not appropriate to describe the full THC PK profile, because the clearance in the terminal elimination phase is overestimated. The THC PK models and the simulated PK profiles are specifically misleading once the dosing interval needs to be planned for multiple dosing scenarios such as chronic pain with 'breakthrough' acute pain superimposed. It is the inaccurate description of the terminal phase profile that results in misspecification of drug accumulation and failure to characterize the washout of THC, leading to increased overdose incidence. In order to analyse THC plasma concentration below the limit of quantification, Ohlsson et al.
[24] dosed both intravenously and by smoking deuterium-labelled THC to nine healthy subjects and followed the plasma concentrations up to 72 h after administration. Consequently, the terminal phase of THC is covered well by the data of this study. Heuberger et al. [18] combined Ohlsson et al.' s data with other published oral and pulmonary dosing data [27] [28] [29] and developed an empirical threecompartment THC PK model, which describes and predicts properly a full characterization of the THC PK profile, as well as integrating all three major administration routes of THC. This model is therefore recommended for dosing interval planning in therapeutic settings, inferences from the PK profile for clinical development, and clinical trial designs, etc. It is worth noting that, since this model was developed based on healthy participants, the predictive result might be biased if used for ill patients. More detailed discussion is presented in the last two paragraphs of this section.
Unlike THC, the PK/PD study of CBD in humans is not extensive with only limited data, and no PK/PD models in the literature were found. Martin-Santos et al. reported that, in healthy male volunteers, the mean ± SD whole blood levels of CBD at 1, 2 and 3 h after administration of 600 mg oral CBD are 0.36 (0.64) ng/ml, 1.62 (2.98) ng/ml and 3.4 (6.42) ng/ml, respectively [30] . Ohlsson et al. dosed intravenously and by smoking deuterium-labelled CBD to five healthy subjects and followed the plasma concentrations up to 72 h after administration [31] . The systematic availability after smoking was found to be 31 ± 13%, and a half-life of 31 ± 4 h after smoking and 24 ± 6 h after IV were reported. However, the concentrations at different sampling times were reported as mean ± SD for the whole tested population, not for each individual participant. This limits the usefulness of developing a rigorous PK model from the data of this study.
Most of the currently available models are empirical and data-driven, derived from healthy volunteers with little pharmacological and physiological mechanism involved. At the same time, rigorous and high-quality clinical trials studying the pharmacokinetics and therapeutic effects of cannabinoids in ill, especially seriously ill, patients (i.e. patients with advanced cancer, AIDS, spasticity in multiple sclerosis, epilepsy, etc.) and relevant PK/PD models are very rare in the literature. Noticeably, a variety of studies disclose that severe illness alters drug disposition in all absorption, distribution, metabolism, and excretion (ADME) phases such as: (1) changes to drug oral absorption and bioavailability due to altered intestinal permeability, fat malabsorption and impaired transport protein function [32, 33] ; (2) changes to drug distribution due to substantial alterations in body composition (e.g., fat mass, fat-free mass and fluid balance) [34, 35] ; (3) changes to drug metabolism due to altered expression and function of liver metabolizing enzymes [36] ; (4) changes to drug elimination due to altered hepatobiliary transport [37] and renal function, although this is less of an issue due to the lipophilicity of the drugs [38] . As a result, it is very likely that the predictive results from models based on healthy subjects models are biased for ill patients.
One method to control this limitation is to develop PK and PD models of cannabinoids from the data extracted from stringent and high-quality Phase I and Phase II studies of ill patients. The challenge might be that the inter-individual variability in pharmacokinetics of the cannabinoids is usually significant in seriously ill patients, e.g. erratic absorption of oral THC, altered body composition. This might lead to obstacles to establishing proper dose-concentration-effect relationships. Compared to other drugs at the development phase, our prior knowledge is relatively rich for medicinal cannabinoids. A large amount of observational data is already available for different diseases for cannabinoids [39] . Also, the long history of using cannabis for recreational purposes provides abundant information on its adverse effects [40, 41] . It is therefore beneficial to consider and integrate these priors (e.g., under a Bayesian analysis framework [42] ), into the PK and PD models of cannabinoids for ill patients. Another method is to integrate pharmacological and physiological mechanisms into PK and PD models of cannabinoids, in order to, for example, extrapolate from healthy volunteers to ill patients. Semi-mechanistic PK models, Physiologically Based Pharmacokinetic (PBPK) models and Quantitative Systems Pharmacology (QSP) models belong to the category of mechanism-based models, in contrast to empirical models. With increased interest in application of mechanism-based models, utilizing these models for the development and use of medicinal cannabinoids is promising. 
